Pernod Ricard to Integrate Malibu-Kahlúa International Brands into the Absolut Company on July 1st, 2009
6.4.2009 13:58:21 CEST | Business Wire | Press release
Pernod Ricard to Integrate Malibu-Kahlúa International Brands into the Absolut Company on July 1 st , 2009
Regulatory News:
Following the successful acquisition of Allied Domecq in 2005 and since its creation in 2006, Malibu-Kahlúa International (MKI), a subsidiary of Pernod Ricard (Paris:RI), has created strong marketing foundations for Malibu, and its two liqueur brands Kahlúa and Tia Maria.
Malibu is the number one coconut-flavoured rums in the world, sold in more than 150 countries. Kahlúa and Tia Maria are the Group two coffee liqueurs, Kahlúa being the world’s leader in its category.
Recognizing the need to significantly increase the level of support behind these dynamic brands and to maximise efficiency, Pernod Ricard has decided to leverage the resources of The Absolut Company (TAC), the Swedish subsidiary in charge of the leading brand of Premium Vodka, Absolut, which offers many synergies.
As a result, the Malibu-Kahlúa International brands will be consolidated within The Absolut Company and will be managed out of Stockholm, Sweden effective with the new fiscal year 2009/10, July 1st , 2009.
About Pernod Ricard
Created by the merger of Pernod and Ricard (1975), the Group has
undergone sustained development, based on both organic growth and
acquisitions.
The purchase of part of Seagram (2001), the
acquisitions of Allied Domecq (2005) and recently of Vin & Sprit (2008)
have made Pernod Ricard the world’s co-leader in wines and spirits with
sales of € 6,589 million in 2007/08.
Pernod Ricard holds one
of the most prestigious brand portfolios in the sector: ABSOLUT Premium
Vodka, Ricard pastis, Ballantine’s, Chivas Regal and The Glenlivet
Scotch whiskies, Jameson Irish Whiskey, Martell cognac, Havana Club rum,
Beefeater gin, Kahlúa and Malibu liqueurs, Mumm and Perrier-Jouët
champagnes, as well Jacob’s Creek and Montana wines.
The
Group favours a decentralised organisation, with 7 Brand Owners and 70
Distribution Companies established in each key market, and employs a
workforce of more than 19,300 people.
Pernod Ricard is
strongly committed to a sustainable development policy and encourages
responsible consumption.
Pernod Ricard is listed on the NYSE
Euronext exchange (Ticker: RI; ISIN code: FR0000120693) and is a member
of the CAC 40 index.
Shareholders’ agenda: 2008/09 3rd Quarter sales– Thursday 30 April 2009
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
Contact:
Pernod Ricard
Francisco de la VEGA / Communication VP
Tel:
+33 (0)1 41 00 40 96
or
Florence TARON / Press Relations
Manager
Tel: +33 (0)1 41 00 40 88
or
Denis FIEVET /
Financial Communication - Investor Relations VP
Tel: +33 (0)1 41 00
41 71
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom